Office Action Analysis — App 19539174 (public record)

Full Analysis

Office Action Response Analysis · Non-Final (CTNF)

App. No. 19/539,174

Art Unit: 1613
Examiner: Kim, Danielle A
Mailed: 07/21/2026
Response period stated in the OA: “3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION”
Rejections: §112(b) ×1§103 ×2ODP ×2
Claims: 25 rejected
Generated: Aug 26, 2026

The most durable footing here is the OA's own admission that Arad does not teach the claimed four-excipient combination (argument 1) and the fully-grounded NACA-versus-NAC compound distinction running through arguments 3-5, all of which operate on the office action's own reasoning rather than unverified reference content — these are the points counsel may weigh pressing on the merits. Several arguments (2 and 5, and the PK-based claim 10 theory generally) rest on specification paragraphs and a chemm.hhs.gov source not in the retrieved record, so counsel should weigh verifying those documents before relying on them and consider whether § 1.132 evidence (criticality of the specific excipient combination, PK unpredictability, unexpected results) is needed to convert attorney argument into rebuttal weight. Given this examiner's documented interview-then-allowance pattern and the availability of clean amendment levers (the claim-6 antecedent-basis fix, and possible narrowing toward a non-routine formulation or NACA-specific PK feature), counsel may weigh a combined argue-and-amend posture advanced through an interview as one path to consider.

Examiner Danielle Kim (AU 1613): allowance rate 35% (n=92); avg 3.84 OAs to allowance; interviews held in 40% of cases, and when an interview was held allowance followed 70% of the time (correlation, not causation); RCE filed in 53% of cases. Based on n=123 applications; USPTO public data, 2016-01-01..2022-12-31. Correlational — it informs, it never decides.

Generated on a published USPTO office action — no confidential disclosure involved. First-pass analysis for attorney review — not a drafted response.

Indicated Allowable Subject Matter & Examiner Interview

Examiner interview (MPEP 713) — a consideration. The strongest candidate arguments below are close calls (see the likely examiner responses in the Argument Bank), so an examiner interview to test the arguments and probe what would put the case in condition for allowance may be worth weighing before filing a written response.

Per-Claim Strategy

An at-a-glance recommendation per rejected claim, composed deterministically from the analysis below. A triage summary for counsel to weigh, not a decision.

Claim	Rejections	Recommended path	Basis	Fallback amendment	Confidence
Claim 1	§103 (obviousness)Double patenting	ArgueStrategy check: re-ranked — The top-applicable argument (Rank 2, excipients-read-out-of-controlled-release-context) barely touches claim 1, which needs only a generic excipient that Arad plainly supplies (¶61, ¶81); the NACA-vs-amide construction (Rank 3) attacks the active-ingredient mapping that controls the whole claim.	Claim construction (#2)	—	moderate
Claim 2	§103 (obviousness)Double patenting	Argue	Conclusory rationale (#3)	—	high
Claim 3	§103 (obviousness)Double patenting	Review — no argument identifiedStrategy check: re-ranked — The bank hooks no argument to claim 3, yet its added wt% range provides no distinction over Arad ¶87, so the NACA construction (Rank 3) is the only theory reaching this claim.	—	—	low
Claim 4	§103 (obviousness)Double patenting	Review — no argument identifiedStrategy check: re-ranked — No argument is hooked to claim 4 and its amounts fall inside Arad's stated range, leaving the foundational NACA construction (Rank 3) as the only reaching theory.	—	—	low
Claim 5	§103 (obviousness)Double patenting	Review — no argument identifiedStrategy check: re-ranked — Because claim 5's 600 mg value is expressly in Arad, only the NACA construction (Rank 3) can carry the claim, yet no argument is hooked to it.	—	—	low
Claim 6	§112(b) (indefiniteness)§103 (obviousness)Double patenting	Argue	Conclusory rationale (#3)	—	moderate
Claims 7–9	§103 (obviousness)Double patenting	Argue	Conclusory rationale (#3)	—	moderate
Claim 10	§103 (obviousness)Double patenting	ArgueStrategy check: re-ranked — The top-applicable NACA construction (Rank 3) does not reach the PK limitation at all, whereas the Spada-misapplication attack (Rank 4) targets the examiner's actual, and weakest, articulated basis for claim 10's distinctive feature.	Claim construction (#1)	—	high
Claims 11–14	§103 (obviousness)	Argue	Claim construction (#1)	—	moderate
Claim 15	§103 (obviousness)Double patenting	Argue	Claim construction (#2)	—	moderate
Claims 16–24	§103 (obviousness)Double patenting	Review — no argument identified	—	—	low
Claim 25	§103 (obviousness)Double patenting	Argue	Claim construction (#1)	—	moderate

Argument Bank

Candidate arguments for counsel, ranked strongest-first — brainstorming inputs for counsel to evaluate, not a drafted response.

In re Spada inherency misapplied — NACA is not the identical structure as NAC

Claim constructionClaim 10Claim 11Claim 12Claim 13Claim 14Claim 25Rebuts: §103 rejection of claims 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25

Strategy check: re-ranked from #2 — The top-applicable NACA construction (Rank 3) does not reach the PK limitation at all, whereas the Spada-misapplication attack (Rank 4) targets the examiner's actual, and weakest, articulated basis for claim 10's distinctive feature.

a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA and NAC ranging from about 200 to 1200 ng/mL

The examiner invokes In re Spada for the proposition that if the prior art teaches the identical chemical structure, the claimed properties are necessarily present. That rationale is predicated on identity of chemical structure; the claims recite plasma concentrations of NACA (an amide), while the PK data the examiner relies on (chemm.hhs.gov) concerns NAC (the acid) — a different compound. For counsel to weigh whether applying NAC's plasma-concentration behavior to NACA via Spada satisfies Spada's identical-structure predicate, or whether the inherency logic is misapplied across two distinct compounds. This argument operates on the OA's own reasoning and the claim language, independent of the unverified chemm.hhs.gov content.

Office action: 'if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada ...'
Office action: 'chemm.hhs.gov teaches that after an oral dose of 200-400 mg of NAC, a peak plasma concentration of 0.35-4 mg/L ... is achieved ...'
Claim 10 recites 'mean plasma concentrations of NACA and NAC'

MPEP § 2112 / § 2112.01 (inherency requires necessity; a property is inherent only if the identical subject matter is disclosed)

Risk The examiner may drop the Spada rationale and rely instead on a §103 predictability/dose-proportionality theory. Because the underlying NAC PK data rests on the unverifiable chemm.hhs.gov, treat its NAC values as given per the grounding rules and press only the identical-structure defect.

Likely examiner response◐ survives — moderate

The examiner can respond that In re Spada is being applied to the same compound the examiner reads Arad as teaching — i.e., if Arad's 'amide' is construed as NACA, then Spada supports inherency of NACA's properties from Arad's NACA, not a cross-compound leap. The examiner can further note that claim 10's PK limitation recites concentrations of BOTH NACA and NAC, so NAC plasma-concentration data (chemm.hhs.gov) is directly on point for the NAC-metabolite portion of the claimed range, and that administering a NAC prodrug is expected to produce NAC in plasma. The examiner may maintain that inherency of a broadly stated range does not require exact identity for the metabolite species.

How to adjust The legally clean point is that Spada's predicate is identity of chemical structure, and NACA (amide) and NAC (acid) are distinct compounds — so if the examiner uses NAC's PK behavior to establish NACA's claimed concentrations, the identity predicate is not met. This survives best if argument 3 succeeds in keeping 'amide prodrug' from being equated to NACA (the two arguments reinforce each other). Note the PK reference (chemm.hhs.gov) is unverified and claim 10 is flagged in OA3 as not-yet-a-firm-missing-finding; verify that source before leaning hard. For counsel to weigh whether the claim's recitation of both NACA and NAC concentrations blunts the cross-compound objection.

Arad discloses NAC and a generic 'amide prodrug,' not specifically NACA

Claim constructionClaim 1Claim 10Claim 15Claim 25

Strategy check: re-ranked from #3 — The top-applicable argument (Rank 2, excipients-read-out-of-controlled-release-context) barely touches claim 1, which needs only a generic excipient that Arad plainly supplies (¶61, ¶81); the NACA-vs-amide construction (Rank 3) attacks the active-ingredient mapping that controls the whole claim.

N-acetylcysteine amide (NACA)

The retrieved Arad claims are directed to 'N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof' (Arad claim 1), and at most reach an 'amide prodrug' of NAC generically among a large list of prodrugs and analogs (Arad claims 6 and 8). The examiner interprets Arad ¶26 'amide' as NACA, but a generic 'amide prodrug of NAC' is not necessarily the specific compound N-acetylcysteine amide; OA2 confirms the retrieved Arad text 'do[es] not use the term N-acetylcysteine amide (NACA).' For counsel to weigh whether the examiner's construction that Arad discloses NACA is supported, or whether NACA is at most one unnamed species within a broad genus of NAC prodrugs/analogs (a genus/species consideration).

Arad claim 1: 'N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.'
Arad claim 6: 'a prodrug of N-acetylcysteine selected from the group consisting of an ester prodrug, an amide prodrug, and an anhydride prodrug.'
OA2: retrieved Arad claims 'do not use the term N-acetylcysteine amide (NACA).'

Claim construction / BRI; genus-species obviousness considerations (MPEP § 2144.08 / § 2131 arrangement)

Risk The examiner may respond that the amide-prodrug genus renders the specific NACA species obvious to try from a finite set (MPEP § 2143 rationale E), or point to the unretrieved specification for an express NACA disclosure. Confirm the Arad specification before treating NACA as absent. Prosecution-history caution: arguing NACA is distinct from NAC prodrugs generally may be used later against equivalents.

Likely examiner response◐ survives — moderate

Because the rejection is under § 103 (not § 102 anticipation), the examiner can argue that identifying the specific species is unnecessary: Arad's express 'amide prodrug of NAC' would have led a PHOSITA directly to N-acetylcysteine amide as the obvious amide of N-acetylcysteine, and selecting a named species from a disclosed class is a predictable choice. The examiner may add that the genus of NAC amide prodrugs is narrow enough — or that the amide of a specific acid is sufficiently pointed — that NACA is the natural reading, and that OA2's observation that the retrieved text 'do[es] not use the term N-acetylcysteine amide (NACA)' addresses only terminology, not what the term denotes to a PHOSITA.

How to adjust Keep the construction attack sharp: press whether 'amide prodrug of NAC' necessarily denotes the primary amide NACA versus a broad class of amide derivatives, and whether the examiner has articulated any reason to pick NACA specifically (genus/species obviousness still needs a rational selection basis, § 2143). Do not overstate this as an anticipation genus/species point since the rejection is § 103. For counsel to weigh coupling this with arguments 4 and 5, since the NACA-vs-NAC distinction is the common thread across all three.

Conclusory KSR rationale for the four-excipient combination of claim 2

Conclusory rationaleClaim 2Claim 6Claim 7Claim 8Claim 9Rebuts: §103 rejection of claims 1, 2, 3, 4, 5, 6, 7, 8, 9

the one or more pharmaceutically acceptable additives, binders, or fillers are selected from microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and stearic acid

The office action itself states that 'Arad does not teach an exact combination of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and stearic acid recited in claim 2' — a record admission that no single Arad teaching supplies the claimed four-component combination. The examiner then supplies the combination through generalized KSR quotations about arranging 'old elements' each performing a known function, but does not articulate why a PHOSITA would select these four particular excipients together, or identify the predictable result their specific combination yields (analysis). Under MPEP § 2143.01 a bare conclusion that a combination 'would have been obvious,' without a rational underpinning tied to the specific selection, is a pressure point for counsel to weigh. Because Arad is fully grounded, this argument rests on the OA's own admission rather than on any unverified reference content.

Office action: 'Arad does not teach an exact combination of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and stearic acid recited in claim 2.'
Office action quoting KSR v. Teleflex regarding arranging 'old elements with each performing the same function it had been known to perform.'

MPEP § 2143 (the seven KSR rationales, each requiring factual findings) and § 2143.01 (articulated reasoning with a rational underpinning; a bare conclusion is insufficient)

Risk The examiner will likely re-articulate that each of the four excipients is a conventional, functionally-named class (filler/disintegrant/lubricant) and that selecting a known combination is routine optimization (MPEP § 2144.05 / § 2144.07). Prosecution-history caution: framing this combination as specially selected or synergistic in the file wrapper may narrow claim scope and invite an unexpected-results burden.

Likely examiner response◐ survives — moderate

The examiner can respond that microcrystalline cellulose (filler/binder), lactose monohydrate (filler), croscarmellose sodium (disintegrant), and stearic acid (lubricant) are each textbook, well-understood tablet excipients performing their ordinary and separate functions, so combining them yields the entirely predictable result of a conventional compressible tablet — precisely the MPEP § 2143 rationale A (combining known elements per known methods for predictable results). The examiner will likely re-anchor to the specification paragraphs cited for each excipient (¶82, ¶84, ¶85, ¶87) and characterize the four-way selection as routine formulation choice requiring no special motivation, not a bare conclusion. Given this examiner's interview propensity (40%, with high downstream allowance), expect the examiner to invite an interview and ask what is non-routine about the specific set.

How to adjust The strength is the OA's own express admission that Arad does not teach the exact four-component combination — press that admission and demand an articulated reason for THESE four together and the specific predictable result (§ 2143.01 rational-underpinning gap). But recognize the examiner can plausibly re-supply routine-excipient reasoning; for counsel to weigh pairing the argument with § 1.132 evidence of criticality/unexpected results for the specific combination (or the claim-24 weight-percent combination), and to consider that if the only reason to select is 'these are all conventional,' amendment toward a demonstrably non-routine formulation feature may be the more durable lever.

No reasonable expectation of reaching the specific claimed PK ranges for NACA

No reasonable expectation of successClaim 10Claim 11Claim 12Claim 13Claim 14Claim 25Rebuts: §103 rejection of claims 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25

mean plasma concentrations ... ranging from about 200 to 1200 ng/mL after administration ... to a human

Oral absorption and plasma exposure for a given active moiety are relatively unpredictable within the general knowledge of the proposed PHOSITA (OA4). The examiner extrapolates from a NAC dose of 200-400 mg to Arad's 600 mg example and to NACA, reasoning only that 'the plasma concentration may be expected to be higher.' For counsel to weigh whether an expectation that a value 'may be' higher meets the reasonable-expectation-of-success standard for arriving at the specific claimed NACA/NAC concentration ranges, particularly across a different compound (NACA vs. NAC) and a different dose. MPEP § 2143.02 requires more than a hope or a general expectation that some result might obtain.

Office action: 'the plasma concentration may be expected to be higher than the concentration range given for 200-400 mg of NAC.'
OA4: 'The relative unpredictability of oral absorption and plasma exposure for a given active moiety would be within this person's general knowledge.'

MPEP § 2143.02 (reasonable expectation of success; unpredictability in the art cuts against it)Evidence needed: A § 1.132 declaration or PK data addressing whether NACA plasma exposure at the claimed doses is predictable from NAC data would strengthen the unpredictability showing.

Risk The examiner may cite general dose-proportionality principles and the breadth of the claimed range (about 200-1200 ng/mL) to argue the ranges are readily reached. The strength of this point depends in part on the unverifiable chemm.hhs.gov data; verify that document before heavy reliance.

Likely examiner response◐ survives — moderate

The examiner can argue the claimed range (about 200 to 1200 ng/mL) is broad — a roughly six-fold span — and Arad's stated purpose is to deliver a therapeutically effective plasma concentration of NAC over a prolonged period, so landing anywhere within so wide a window is a predictable, not surprising, result and plasma concentration is a result-effective variable subject to routine optimization by dose selection. The examiner may reiterate the dose-scaling logic (200-400 mg to Arad's 600 mg example) and note that unpredictability of oral absorption is an attorney assertion (OA4) unsupported by evidence, whereas § 2143.02 does not demand absolute predictability, only a reasonable expectation.

How to adjust The reasonable-expectation-of-success point is strongest when combined with the NACA-vs-NAC compound difference (arguments 3 and 4) and a genuinely unpredictable-art showing — but that generally needs evidence (a § 1.132 declaration on absorption/PK unpredictability), not attorney argument alone. Note the breadth of the claimed range cuts against the applicant; for counsel to weigh whether the range as claimed is narrow enough to make 'may be higher' insufficient. Verify chemm.hhs.gov and the Arad specification dose disclosures before pressing; claim 10 is verification-flagged in OA3.

Arad's excipients read out of its controlled-release/osmotic context (lactose monohydrate is an osmagent)

Mischaracterized referenceClaim 1Claim 2Rebuts: §103 rejection of claims 1, 2, 3, 4, 5, 6, 7, 8, 9

A tablet comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient

The retrieved Arad claims show an invention fundamentally directed to controlled-release architecture — sustained-release/immediate-release components, matrices with rate-controlling polymers, and osmotic push/pull layers with rate-controlling membranes (Arad claims 1, 2, 10, 11, 14, 16). Of the four excipients recited in instant claim 2, the only one that appears in the retrieved Arad claim text is lactose monohydrate, and there it functions as an 'osmagent' within the osmotic delivery system (Arad claim 26), a role distinct from a simple filler in a conventional tablet. The examiner's citations for microcrystalline cellulose (¶82), croscarmellose sodium (¶84), and stearic acid (¶85) point to specification paragraphs that are not present in the retrieved Arad text and are therefore not verifiable from the available record. For counsel to weigh whether extracting individually-listed excipients from Arad's controlled-release framework, read as a whole, mischaracterizes the reference (MPEP § 2141.02).

Arad claim 26: osmagent 'selected from the group consisting of ... lactose monohydrate ...'
Arad claim 1 (SR component with release-controlling architecture) and claims 14/16 (osmotic push/pull layers, rate-controlling membrane)
OA2 reality check: 'the examiner's cited paragraphs ... are in the specification, which is not part of the fetched claims/abstract.'

MPEP § 2141.02 (reference must be considered in its entirety) and § 2143.01 (a modification that reworks the reference's principle of operation is unsupported)Evidence needed: Obtain the Arad specification (¶82, ¶84, ¶85, ¶87, ¶120) to confirm whether these excipients are disclosed as general tablet components or only within the controlled-release/osmotic embodiments.

Risk The examiner will point to the cited specification paragraphs as disclosing these excipients as conventional tablet components independent of the osmotic embodiment. Counsel should obtain the Arad specification before pressing hard, since the excipient teachings rest on spec paragraphs not in the retrieved text. Prosecution-history caution: characterizing the claimed tablet as non-controlled-release may narrow scope against later-added release features.

Likely examiner response⚠ fragile — the comeback likely defeats it

The examiner can answer that a single excipient serving as an osmagent in Arad's osmotic embodiment does not disqualify that same material from also serving as a filler — excipients are routinely multifunctional, and Arad's disclosure is read for all it teaches a PHOSITA, not confined to one embodiment. The examiner will note that the cited specification paragraphs (¶82, ¶84, ¶85) — which the applicant cannot verify from the retrieved claims/abstract — are asserted to disclose microcrystalline cellulose, croscarmellose sodium, and stearic acid directly, so the 'read out of context' framing attacks the reference in isolation rather than the rejection as applied. Using lactose in a controlled-release system is not a criticism or discouragement of using it as a conventional filler, so no teaching-away under MPEP § 2141.02 is shown.

How to adjust This argument's factual premise depends on specification paragraphs (¶82, ¶84, ¶85, ¶87) that are NOT in the retrieved record — verify the Arad specification before pressing, because if those paragraphs disclose the excipients as plain excipients the mischaracterization theory collapses. Note the exemplary/multifunctional-use problem: the osmagent role is one function, not a limiting definition. For counsel to weigh reframing only if Arad affirmatively criticizes conventional immediate-release tablets (a genuine teach-away); otherwise fold any surviving value into argument 1 and de-emphasize this as a standalone.

Antecedent-basis rejection of claim 6 — construction lever ('the lactose' = the lactose monohydrate of claim 2)

Definiteness rebuttalClaim 6Rebuts: §112(b) rejection of claim 6

the lactose

The §112(b) rejection rests on antecedent basis: parent claim 2 recites 'lactose monohydrate,' while claim 6 recites 'the lactose.' For counsel to weigh a BRI-based construction that 'the lactose' reasonably refers to the 'lactose monohydrate' introduced in claim 2, such that the scope is reasonably certain under MPEP § 2173.02 / In re Packard. This is a low-cost point most cleanly resolved by amendment to conform the terminology; counsel should not argue that the simultaneous §112(b) and §103 rejections are internally inconsistent, as compact prosecution permits both.

Claim 2: additives 'selected from microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and stearic acid.'
Claim 6: 'wherein the lactose is 0, 1, 2, ... to 66 wt. %'
Office action: 'Claim 6 recites the limitation "the lactose" ... There is insufficient antecedent basis for this limitation in the claim.'

MPEP § 2173.02 / In re Packard (examination definiteness standard) — do NOT cite Nautilus in prosecution

Risk The examiner is likely to maintain the antecedent-basis defect regardless of a construction argument; an amendment conforming 'the lactose' to 'the lactose monohydrate' is the clean fix. Minimal prosecution-history exposure.

Likely examiner response◐ survives — moderate

The examiner can simply maintain the § 112(b) antecedent-basis rejection: parent claim 2 introduces 'lactose monohydrate' while claim 6 recites 'the lactose,' and under In re Packard the discrepancy leaves a term whose referent is arguably unclear until conformed. A BRI reading that 'the lactose' equals 'lactose monohydrate' is reasonable, but the examiner is entitled to require the claim to be clear on its face and will most efficiently withdraw the rejection upon a conforming amendment rather than on argument.

How to adjust This is a low-stakes, amend-first item — the cleanest resolution is conforming the terminology so 'the lactose' matches 'lactose monohydrate,' which moots the rejection without expending argument capital. Do NOT argue that the simultaneous § 112(b) and § 103 rejections are internally inconsistent (compact prosecution, MPEP § 2173.06(II), expressly permits both). Handle by amendment and reserve argument for the substantive § 103 points.

Verify-first: whether chemm.hhs.gov supplies NACA-specific (not merely NAC) plasma concentrations

Missing elementClaim 10Claim 11Claim 12Claim 13Claim 14Claim 25Rebuts: §103 rejection of claims 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25

mean plasma concentrations of NACA ... after administration of the pharmaceutical composition to a human

This is a verify-first posture, NOT a firm missing-element finding. The PK values in the rejection rely on chemm.hhs.gov, which was never retrieved and is unverifiable; per the grounding discipline its characterization is taken as given and no missing-element conclusion may be drawn against it. The genuinely contestable question — whether chemm.hhs.gov (or the unretrieved Arad specification) supplies NACA-specific plasma concentrations within the claimed ranges, as opposed to NAC data alone — should be resolved by obtaining and verifying the document before counsel relies on any distinction. This item ranks below every argument that rests on the fully-grounded Arad claim text.

Grounding block: chemm.hhs.gov is UNVERIFIABLE — reference text was not retrieved.
OA3: 'CANNOT BE RECORDED AS A FIRM MISSING FINDING — flagged for verification only.'

MPEP § 2131 (anticipation/inherency requires each element be disclosed) — applied here only as a verification prompt, not a conclusionEvidence needed: Obtain and review chemm.hhs.gov (pg. 11 cited) and the Arad specification to determine whether either supplies NACA-specific (vs. NAC) human plasma-concentration data within the claimed ranges.

Risk No conclusion can be asserted until chemm.hhs.gov is obtained; asserting a missing element now would be an unsupported negative about an unseen reference.

Examiner's Characterization of the Cited Art

Note

What each cited reference actually discloses, checked against what the examiner said it teaches — limited to the reference text available to the analysis.

Arad (WO 2009/137827 A2)

WO 2009137827 A2Claim text retrieved

The available text (abstract and claims 1-54) describes a CONTROLLED-RELEASE composition of N-acetylcysteine (NAC), or a salt, solvate, prodrug, and/or analog thereof, that delivers a therapeutically effective plasma concentration of NAC over a prolonged period (more than about 2 hours; up to about 24 hours), used to reduce systemic/vascular inflammation. The invention as claimed centers on release-controlling architecture — sustained-release (SR) and immediate-release (IR) components, matrices with rate-controlling polymers, osmotic push/pull layers, and rate-controlling membranes. The available text does not contain paragraph-numbered disclosure; the examiner's cited paragraphs (¶26, ¶61, ¶67, ¶81, ¶82, ¶84, ¶85, ¶87, ¶120) are in the specification, which is not part of the fetched claims/abstract. The available claims mention an 'amide prodrug' of NAC (claim 6) and 'lactose monohydrate' as an osmagent (claim 26), but do not use the term N-acetylcysteine amide (NACA).

Claim element	Examiner asserts	Reference discloses	Evidence
Active agent 10-90 wt% / NACA weight percent ranges (claims 3, 4, 6-9, 17-24)	Arad teaches 10-90% of the active agent (para. 87), interpreted as including NACA, with the remainder as excipients/fillers.	Not found in available text	The available claims and abstract do not recite any weight-percent range for the active agent. Paragraph 87 is in the specification, not the fetched text, and should be checked.
600 mg active-ingredient example (claims 5, 19)	In one example the composition comprises 600 mg of the active ingredient (para. 120).	Not found in available text	The available claims and abstract contain no worked examples and no 600 mg dosage figure. Paragraph 120 is in the specification, not the fetched text, and should be checked.
NACA (N-acetylcysteine amide) (claim 1)	Arad teaches NAC that may comprise amide (para. 26), interpreted as NACA.	Partially supported	Available claim 6 discloses "a prodrug of N-acetylcysteine selected from the group consisting of an ester prodrug, an amide prodrug, and an anhydride prodrug," but the available text nowhere names 'N-acetylcysteine amide' or 'NACA.' Whether an 'amide prodrug' of NAC equates to NACA is an interpretive step; paragraph 26 is in the specification, not the fetched text, and should be checked.
Therapeutically effective plasma concentration over time (basis for PK reasoning, claims 10-14, 25)	Arad teaches that its composition reaches a therapeutically effective plasma concentration over time (para. 2) for NAC and presumably NACA.	Supported	Abstract: "provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time"; claim 1 recites "a therapeutically effective plasma concentration of N-acetylcysteine over more than about 2 hours." Note the available text speaks of NAC plasma levels generally and does not state the specific numeric plasma-concentration values (e.g., about 200-1200 ng/mL) or the NACA-specific values recited in the instant claims.
Tablet (claim 1)	Arad teaches tablet compositions (para. 67).	Not found in available text	The available claims and abstract describe an oral 'composition' with SR/IR components, matrices, and osmotic layers, but do not use the term 'tablet.' Paragraph 67 is in the specification, which is not in the fetched text — the full specification should be checked.
NACA-acceptable biocompatible excipient / additives, binders, or fillers (claim 1)	Arad teaches excipients (para. 61) and binders (para. 81).	Not found in available text	The available text does not contain a general recitation of 'excipients' or 'binders'; paragraphs 61 and 81 are in the specification, not the fetched claims/abstract. The full specification should be checked.
Microcrystalline cellulose (claim 2)	Arad discloses microcrystalline cellulose (para. 82).	Not found in available text	The available text does not contain 'microcrystalline cellulose'; the fetched claims list cellulose-based rate-controlling polymers (e.g., hydroxypropyl cellulose, methyl cellulose, cellulose acetate) but not microcrystalline cellulose. Paragraph 82 is in the specification and should be checked.
Croscarmellose sodium (claim 2)	Arad discloses croscarmellose sodium (para. 84).	Not found in available text	The available text does not contain 'croscarmellose sodium.' Paragraph 84 is in the specification, not the fetched claims/abstract, and should be checked.
Stearic acid (claim 2)	Arad discloses stearic acid (para. 85).	Not found in available text	The available text does not contain 'stearic acid.' Paragraph 85 is in the specification, not the fetched claims/abstract, and should be checked.
Lactose monohydrate (claim 2)	Arad discloses lactose monohydrate (para. 82).	Partially supported	Available claim 26 recites "lactose monohydrate" — but as an osmagent within an osmotic pull layer, not identified as a tablet filler. The examiner's cite (¶82) is in the specification and may present it in a different context; the full specification should be checked.

Abstract; claim 1; claims 53-54"The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time." Claim 1 recites an SR component providing effective plasma NAC "over more than about 2 hours," and claims 53-54 extend this to "more than about 4 hours" and "about 2 to about 24 hours."The reference's stated invention is a sustained/controlled-release system. Whether this framing bears on the obviousness combination with the instant simple-tablet and PK claims, and on MPEP § 2141.02 consideration of the reference as a whole, is for counsel to weigh.
Claim 6"The composition of claim 1 or 2, wherein the SR and/or IR component comprises a prodrug of N-acetylcysteine selected from the group consisting of an ester prodrug, an amide prodrug, and an anhydride prodrug."This is the only place in the available text that mentions an 'amide' in connection with NAC — the examiner interprets ¶26 'amide' as NACA. The claim frames the amide as a 'prodrug' of NAC, not as N-acetylcysteine amide by name; whether an 'amide prodrug' reads on NACA is for counsel to assess.
Claim 3; claim 8Claim 3 describes a prodrug/analog of NAC "which is less polar than N-acetylcysteine and is absorbable in the lower gastrointestinal tract." Claim 8 lists many named analogs (e.g., DiNAC, Carbocisteine, glutathione, S-nitroso-NAC, etc.) and "derivatives of reacting a reactive derivative of p-isobutylphenylpropionic acid and NAC (e.g., an amide)."Provides context on how the reference characterizes NAC derivatives — as less-polar prodrugs/analogs for controlled release. N-acetylcysteine amide (NACA) is not among the specifically named analogs in the available text.
Claim 26"The composition of claim 25, wherein the osmagent is selected from the group consisting of ... carbohydrates such as raffinose, sucrose, glucose, lactose monohydrate, and a blend of fructose glucose."Lactose monohydrate does appear in the available text — but as an OSMAGENT within an osmotic pull layer, not as a general tablet filler. Whether this context matches the excipient role in instant claim 2 is for counsel to weigh.

Element-by-Element Claim Chart

Claim 1 — §103 (Arad)

Status glyph	Claim element	Status	Disclosure / notes	Location
◐	A tabletArad	Arguably taught	The examiner cites Arad ¶[0067] for 'tablet' (per OA1), but that paragraph is in the specification, which is NOT within the retrieved claims/abstract (analysis) — the fetched Arad claims describe a 'composition' built on controlled-release architecture (SR/IR components, matrices, osmotic push/pull layers), not expressly a 'tablet.' For counsel to weigh: verify the ¶[0067] tablet disclosure against the actual specification before treating this as settled.	Arad, abstract; Arad, claims 1-2, 10-11
◐	N-acetylcysteine amide (NACA)Arad	Arguably taught	Examiner cites Arad ¶[0026] 'amide,' interpreted as NACA (per OA1); that paragraph is not in the retrieved text (analysis). What IS verifiable: Arad claim 6 recites an 'amide prodrug' of NAC as one member of a group (ester/amide/anhydride), and claim 8 lists numerous analogs — but the retrieved Arad text NEVER uses the term 'N-acetylcysteine amide' or 'NACA.' Contestable genus-vs-species point for counsel (§103): an 'amide prodrug' genus is not the same as claimed NACA, and Arad frames the amide as a 'prodrug' rather than the claimed active. Verify whether the specification names NACA specifically.	Arad, claim 6; Arad, claim 8; Arad, abstract
◐	a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillersArad	Arguably taught	Examiner cites Arad ¶[0061] (excipients) and ¶[0081] (binders) (per OA1); those paragraphs are not in the retrieved text (analysis). The retrieved Arad claims disclose polymers and osmagents, but their disclosed function is release-control/osmotic, not general 'excipient/binder/filler.' For counsel to weigh: verify the cited paragraphs.	Arad, claims 10-13 (rate-controlling polymers); Arad, claim 26 (osmagents incl. lactose monohydrate)

Claim 2 — §103 (Arad)

Status glyph	Claim element	Status	Disclosure / notes	Location
—	the additives/binders/fillers selected from microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and stearic acidArad	Not taught	The office action itself states 'Arad does not teach an exact combination of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and stearic acid recited in claim 2' — a record admission that the specific four-component combination is not disclosed; the examiner supplies it via KSR combination reasoning, not by a single teaching. Of the four, only lactose monohydrate is verifiable in the retrieved Arad text, and there it is disclosed as an 'osmagent' (Arad claim 26), a distinct functional role from a filler/binder. The individual disclosures of microcrystalline cellulose (¶[0082]), croscarmellose sodium (¶[0084]), and stearic acid (¶[0085]) cited by the examiner are in the specification, not in the retrieved text (analysis) — verify each. Contestable KSR point for counsel: whether picking these four particular excipients from a larger list is the 'predictable use of prior art elements according to their established functions.'	Arad, claim 26 (lactose monohydrate); Office action ¶8 (examiner's own statement)

Claim 5 — §103 (Arad)

Status glyph	Claim element	Status	Disclosure / notes	Location
◐	the tablet comprises 100, 200, 250, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, 1,000, 1,250, 1,500, 1,750, or 2,000 mg of NACAArad	Arguably taught	The 600 mg example is cited to Arad ¶[0120], which is in the specification and not within the retrieved claims/abstract (analysis) — verify. Note the recited amount is of NACA specifically; per the claim-2/claim-1 analysis the '600 mg active agent' in Arad is described for NAC (or its prodrug/analog genus), so for counsel to weigh whether the amount is disclosed as NACA.	Office action ¶8 (examiner cites Arad ¶[0120], 600 mg)

Claim 6 — §103 (Arad)

Status glyph	Claim element	Status	Disclosure / notes	Location
◐	wherein the lactose is 0 ... to 66 wt. % with corresponding adjustments to other componentsArad	Arguably taught	Separate from the §103 posture: this claim also carries a §112(b) antecedent-basis rejection — 'the lactose' (claim 6) lacks an antecedent because parent claim 2 recites 'lactose monohydrate,' not 'lactose.' That is a claim-drafting/indefiniteness issue, not a reference-teaching question (no reference is asserted for the §112 point). For the §103 range: the specific 0-66 wt% range is cited to Arad specification content not in the retrieved text (analysis) — verify. For counsel to weigh whether the §112 issue is addressable by a clarifying amendment concept aligning the antecedent term.	Arad, claim 26 (lactose monohydrate as osmagent)

Claim 10 — §103 (Arad in view of chemm.hhs.gov)

Status glyph	Claim element	Status	Disclosure / notes	Location
◐	A pharmaceutical composition in an oral tablet comprising N-acetylcysteine amide (NACA)Arad	Arguably taught	Same NACA genus-vs-species and 'tablet'-cited-to-spec caveats as charted for claim 1 (analysis). Verify the specification's use of 'NACA' and 'tablet.'	Arad, claim 6; Arad, claim 8; Arad, abstract
◐	the composition has a PK profile comprising mean plasma concentrations of NACA and NAC ranging from about 200 to 1200 ng/mL after administration to a humanArad, chemm.hhs.gov	Arguably taught	VERIFY-FIRST (provisional, ranks below fully-grounded points): chemm.hhs.gov was not retrieved and its text is unverifiable — the examiner's characterization is taken as given, so no conclusion that the limitation is absent from it may be drawn. Two contestable points to develop only after obtaining chemm: (1) per the examiner's own account, chemm reports plasma concentrations for NAC, whereas the claim requires plasma concentrations of NACA (and NAC) — confirm whether chemm addresses NACA at all; (2) the examiner's inherency theory under In re Spada assumes 'identical chemical structure' — for counsel to weigh whether Arad in fact discloses the identical NACA tablet such that the claimed PK is necessarily present. Obtain and verify the chemm.hhs.gov pg. 11 teaching before relying on any distinction.	Arad, claim 1 / abstract (therapeutically effective plasma concentration of NAC over time); Office action ¶9 (chemm.hhs.gov, pg. 11: 200-400 mg NAC → 0.35-4 mg/L peak in 1-2 hours)

Claim 11 — §103 (Arad in view of chemm.hhs.gov)

Status glyph	Claim element	Status	Disclosure / notes	Location
◐	the mean NACA plasma concentration is about 400-600 ng/mL after a 250 mg QD dosing regimen with NACA Tablet, 250 mgArad, chemm.hhs.gov	Arguably taught	VERIFY-FIRST (provisional, ranks below fully-grounded points): chemm.hhs.gov is unverifiable — examiner's characterization taken as given, no missing-element conclusion drawn. Per the examiner's account chemm reports 350-400 ng/mL peak for a 200-400 mg NAC dose; this claim recites a specific 400-600 ng/mL window for NACA after a specific 250 mg QD regimen of a 250 mg NACA tablet. For counsel to weigh, after obtaining chemm, whether the specific dose/regimen and the NACA-specific value are supplied by the asserted references or reached only by the examiner's 'expected to be higher' extrapolation (Office action ¶9).	Office action ¶9 (chemm.hhs.gov, pg. 11); Arad, abstract

Claim 24 — §103 (Arad in view of chemm.hhs.gov)

Status glyph	Claim element	Status	Disclosure / notes	Location
—	the lactose is about 8 wt%, the microcrystalline cellulose about 34 wt%, the croscarmellose sodium about 5.0 wt%, the stearic acid about 1.0 wt%Arad	Not taught	This claim recites a specific four-component excipient combination at specific weight percentages. The office action provides no verifiable teaching of these particular values in combination — the examiner relies on broad 'about 10-90% active / remainder excipients' reasoning (Arad ¶[0087], cited to specification not in retrieved text (analysis)) and the KSR combination rationale, and the office action itself admits Arad does not teach the exact four-excipient combination. Only lactose monohydrate is verifiable in the retrieved Arad text and only as an osmagent (Arad claim 26). Contestable point for counsel: whether the specific values and combination are more than the predictable arrangement the examiner asserts. NOTE ON OMITTED CLAIMS: to stay within the 8-claim cap, claims 3, 4, 7, 8, 9 (wt% dependents paralleling the same excipient/amount analysis), 12-14 (PK dependents paralleling claim 11), 15-16 (paralleling claims 1-2), 17-23 (paralleling claims 3-9), and 25 (charted below) were not separately element-charted; the analyses above apply to them by parallel. Claim 25 is charted separately because it is an independent claim.	Arad, claim 26 (lactose monohydrate); Office action ¶8/¶9 (examiner relies on 'about 10-90%' ranges, ¶[0087])

Claim 25 — §103 (Arad in view of chemm.hhs.gov)

Status glyph	Claim element	Status	Disclosure / notes	Location
◐	A pharmaceutical composition in an oral tablet comprising NACA and a NACA-acceptable, biocompatible excipient and optionally additives, binders, or fillersArad	Arguably taught	Same NACA genus-vs-species and 'tablet'/excipient caveats as charted for claims 1 and 10 (analysis) — the composition/excipient teachings the examiner relies on are cited to specification paragraphs not in the retrieved text; verify.	Arad, claim 6; Arad, claim 8; Arad, claim 26; Arad, abstract
◐	PK profile comprising mean plasma concentrations of NACA from about 200 ... to 1,200 ng/mL after administration to a humanArad, chemm.hhs.gov	Arguably taught	VERIFY-FIRST (provisional, ranks below fully-grounded points): chemm.hhs.gov unverifiable — characterization taken as given, no missing-element conclusion. This claim's PK limitation is stated for NACA specifically; per the examiner's account chemm addresses NAC. Same inherency-theory caveat as claim 10 (whether Arad discloses the identical NACA structure/tablet so the PK is necessarily present). Obtain and verify chemm before relying on any NAC-vs-NACA distinction.	Office action ¶9 (chemm.hhs.gov, pg. 11); Arad, claim 1 / abstract; In re Spada (inherency, cited in Office action ¶9)

Elements not shown by the cited art (3)

Claim 2 — “the exact combination of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and stearic acid”: Arad is fully grounded and the office action itself expressly states 'Arad does not teach an exact combination of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and stearic acid recited in claim 2' — a record admission that no single Arad teaching discloses the four-component combination. The examiner supplies the combination only through KSR combination reasoning. Of the four components, only lactose monohydrate is verifiable in the retrieved Arad claims (claim 26, disclosed as an osmagent, a distinct function). This is a prima-facie-case pressure point for counsel to weigh under §103: whether selecting and combining these four particular excipients is the predictable arrangement the examiner asserts.
Claim 24 — “the specific weight-percent combination — lactose about 8 wt%, microcrystalline cellulose about 34 wt%, croscarmellose sodium about 5.0 wt%, stearic acid about 1.0 wt%”: Building on the claim-2 record admission, no verifiable Arad teaching discloses these four specific excipients at these specific weight percentages in combination; the examiner relies on a broad 'about 10-90% active / remainder excipients' rationale (Arad ¶[0087], cited to specification not in the retrieved text) plus KSR. For counsel to weigh whether the specific values in combination are supplied by any asserted reference.
Claim 10 — “mean plasma concentrations of NACA (not merely NAC) within the claimed range after administration to a human”: CANNOT BE RECORDED AS A FIRM MISSING FINDING — flagged for verification only. The reference the examiner relies on for the PK values, chemm.hhs.gov, was never retrieved (unverifiable); per the grounding rules its characterization is taken as given and no missing-element conclusion may be drawn against it. The contestable question — whether any asserted reference supplies an NACA-specific (as opposed to NAC) plasma concentration — must be resolved by obtaining and verifying chemm.hhs.gov (and the Arad specification) first. Ranks below the fully-grounded claim-2/claim-24 findings above.

Rejection Map

§112(b)Indefiniteness — claims 6

Claim 6 recites 'the lactose' in line 1, but its parent claim 2 recites 'lactose monohydrate,' not 'lactose.' The examiner finds there is insufficient antecedent basis for the limitation 'the lactose' in the claim.

§103Obviousness — claims 1, 2, 3, 4, 5, 6, 7, 8, 9MPEP §2143(A)

Arad WO 2009137827 A2

Arad teaches tablet compositions (para. 67) comprising NAC that may comprise amide (para. 26), interpreted as NACA. Arad teaches excipients (para. 61), binders (para. 81), and individually discloses microcrystalline cellulose (para. 82), lactose monohydrate (para. 82), croscarmellose sodium (para. 84), and stearic acid (para. 85). Arad teaches 10-90% active agent (para. 87) and a 600 mg example (para. 120). The examiner acknowledges Arad does not teach the exact combination of all four excipients recited in claim 2, but applies KSR reasoning that selecting various combinations of individually disclosed ingredients from within a prior art disclosure to arrive at a composition yielding no more than one would expect is obvious. The examiner quotes KSR v. Teleflex regarding arranging old elements each performing the same known function.

§103Obviousness — claims 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25MPEP §2143(A)

Arad WO 2009137827 A2NPLchemm.hhs.gov

Arad is applied as in the rejection of claims 1-9 for the composition teachings. For the PK profile limitations of claims 10-14 and 25 (plasma concentrations of NACA and NAC), the examiner cites chemm.hhs.gov, which teaches that after an oral dose of 200-400 mg of NAC, a peak plasma concentration of 0.35-4 mg/L (350-400 ng/mL) is achieved within 1-2 hours (pg. 11). The examiner reasons that since Arad teaches 600 mg, the plasma concentration may be expected to be higher than for 200-400 mg. The examiner also invokes inherency under In re Spada: if the prior art teaches the identical chemical structure, the disclosed/claimed properties are necessarily present. Additionally cites MPEP § 2144.07 for prima facie obviousness of selecting a known material based on its recognized suitability.

ODPDouble patenting — claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25

Copending Application

Provisional nonstatutory double patenting rejection. Claims 1-21 of copending Application No. 19/465,413 are nearly identical in components and range of amounts/concentrations. Claims 1-11 of the reference application correspond to instant claims 1-10; claim 12 corresponds to instant claim 15; claim 13 corresponds to instant claim 16; claims 14-20 correspond to instant claims 17-24; claim 21 corresponds to instant claim 25.

ODPDouble patenting — claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 15, 16, 24

Copending Application

Provisional nonstatutory double patenting rejection. Claims 1, 3-9, 33-37 of copending Application No. 19/173,475 are nearly identical in components and range of amounts/concentrations. Claim 1 of the reference application corresponds to instant claims 1 and 2; claims 3-9 correspond to instant claims 3-9; claim 33 corresponds to instant claims 1, 2, 15, and 16; claim 34 corresponds to instant claims 6 and 24; claims 35-37 correspond to instant claim 24.

References Cited

AradWO 2009137827 A2
NPLchemm.hhs.gov

Record & Grounding

Grounding Summary

Note

How each cited reference was grounded. A reference the analysis could only read through the office action’s characterization is flagged — its findings are limited to what the examiner said, not the reference itself.

Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammationWO2009137827A2: Claim text retrieved
Copending Application19465413: Not retrieved — analysis limited to the OA's characterizationthis number did not resolve to a document — verify it
Copending Application19173475: Not retrieved — analysis limited to the OA's characterizationthis number did not resolve to a document — verify it

Data Egress Log

Note

Your uploads stay in-boundary. External retrieval was limited to public patent-number lookups: 1 fetch. No claim text, no client material left the environment.

Patents fetched by number: WO2009137827A2
Documents processed: afa6ef1d-7cdf-4418-bba7-15984047ecc1.pdfoffice action
d1bbbec5-885a-4a44-9b27-7a756ce4d33f.pdfclaims
Processed in-boundary — never transmitted externally.

Obviousness Framework

Field of endeavor: Oral solid-dosage pharmaceutical formulation, specifically tablets containing N-acetylcysteine amide (NACA) together with pharmaceutically acceptable excipients, and the pharmacokinetic (plasma-concentration) behavior of such tablets after administration to humans (pending claims 1-25).
PHOSITA: For argument purposes (a proposed construction for counsel to adopt or adjust, not a factual finding): a pharmaceutical formulation scientist with an advanced degree (or a bachelor's/master's degree plus several years of industry experience) in pharmaceutics, pharmaceutical chemistry, or a related discipline, familiar with tablet-formulation techniques, the functional roles of common excipients (fillers, binders, disintegrants, lubricants such as microcrystalline cellulose, lactose, croscarmellose sodium, and stearic acid), and with pharmacokinetic evaluation of orally administered drugs. The relative unpredictability of oral absorption and plasma exposure for a given active moiety would be within this person's general knowledge.A construction for argument — not asserted as fact.

Reference	Analogous art	Rationale
Arad (WO 2009/137827 A2)	Analogous	Same field of endeavor under MPEP § 2141.01(a) prong (1): Arad is directed to oral pharmaceutical compositions of N-acetylcysteine 'or a salt, solvate, prodrug, and/or analog thereof' (Arad claim 1; abstract), i.e., oral solid-dosage formulation of an NAC-based active, which overlaps the field of the pending NACA tablet claims. Note (analysis): although analogous as to field, Arad's disclosed invention is specifically a CONTROLLED-RELEASE architecture (SR/IR components, rate-controlling polymers, osmotic push/pull layers, rate-controlling membranes), which is relevant to the combination analysis below rather than to analogous-art status.
chemm.hhs.gov	Contestable	Under MPEP § 2141.01(a): the fetched record does not contain the chemm.hhs.gov text itself, only the examiner's characterization of it as teaching NAC oral pharmacokinetics (peak plasma concentration after a 200-400 mg oral NAC dose, per OA pg. 11). Whether it is in the same field of endeavor (formulation) or merely 'reasonably pertinent' to the inventor's problem (achieving a defined NACA/NAC plasma profile from a tablet) is for counsel to weigh; it appears to describe NAC pharmacokinetics rather than NACA formulation, and its analogous-art status cannot be fully assessed without the underlying document. The available text does not contain the reference itself.

§103 rejection of claims 1-9 over Arad alone. The examiner maps Arad to a NACA tablet with excipients: tablet (¶67), 'amide' (¶26) interpreted as NACA, excipients (¶61), binders (¶81), microcrystalline cellulose/lactose monohydrate (¶82), croscarmellose sodium (¶84), stearic acid (¶85), 10-90% active (¶87), 600 mg example (¶120). The examiner concedes Arad does not teach the exact four-excipient combination of claim 2 and supplies KSR 'arrangement of old elements' reasoning.

Arad

Motivation asserted Per the office action, selecting various combinations of individually disclosed ingredients from within a single prior-art disclosure to arrive at a composition 'yielding no more than one would expect from such an arrangement' is obvious under KSR v. Teleflex; since Arad teaches the individual components, one of ordinary skill would select the combination with a reasonable expectation of success.

Othermoderate
Claim-construction / mapping issue for counsel to weigh: the pending claims recite 'N-acetylcysteine amide (NACA)' specifically, whereas the available Arad text refers to an 'amide prodrug' of N-acetylcysteine (Arad claim 6) and lists numerous NAC analogs (Arad claim 8) without ever using the term NACA. Whether Arad's generic 'amide prodrug' language reads on the specific compound NACA is a construction question the examiner resolved by 'interpretation' (¶26) rather than by an express teaching. This mapping is contestable and is not conceded by any stipulation as to reference content.
Hindsight reconstructionmoderate
The examiner picks exactly four specific excipients (microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, stearic acid) from separate portions of Arad's disclosure and reassembles them into the precise combination of claim 2, while conceding Arad 'does not teach an exact combination' of the four. MPEP § 2143.01 cautions that the reasoning to modify or select must have a rational underpinning independent of the applicant's own disclosure; selecting precisely the claimed set from generic lists may reflect the pending claims as a roadmap rather than any direction in Arad. Counsel may weigh whether the selection is impermissible hindsight.
Conclusory motivationmoderate
The articulated rationale is a general recitation of KSR 'arrangement of old elements' language without factual findings tying these particular four excipients to a predictable result in a NACA tablet. Under MPEP § 2143 / § 2143.01, a KSR rationale still requires an articulated line of reasoning with a rational underpinning; a bare statement that combining individually disclosed ingredients 'yields no more than one would expect' may be insufficient. For counsel to assess whether the examiner supplied the required findings.
Otherweak
Record-verification gap (analysis): the reference reality check reports that the fetched Arad text (abstract and claims 1-54) does not contain paragraph-numbered disclosure, so the examiner's specific pin-cites (¶26, ¶61, ¶67, ¶81, ¶82, ¶84, ¶85, ¶87, ¶120) could not be confirmed against the available record. The available text does not contain these paragraphs; counsel should verify each cited paragraph against the full Arad specification before relying on this weakness, as absence from the fetched excerpt does not establish absence from the reference.
Destroys principle of operationweak
The available Arad claims frame the invention around controlled/sustained-release architecture — SR and IR components, matrices with rate-controlling polymers, osmotic push/pull layers, and rate-controlling membranes (Arad claims 1-2, 10-34) — delivering NAC 'over more than about 2 hours' up to 'about 24 hours' (Arad claims 1, 53-54). The pending claims recite a plain tablet with conventional excipients and no release-controlling structure. Counsel may weigh whether extracting excipients from Arad while discarding its release-controlling principle of operation (MPEP § 2143.01) undermines the combination; this is tempered by the fact that the excipient teachings are cited from the specification portions not in the fetched text.

§103 rejection of claims 10-25 over Arad in view of chemm.hhs.gov. Arad supplies the composition teachings as in the claims 1-9 rejection; chemm.hhs.gov supplies the pharmacokinetic (plasma-concentration) limitations of claims 10-14 and 25. The examiner reasons that because Arad teaches a 600 mg dose, plasma concentration would be expected higher than chemm's 200-400 mg NAC data, and invokes inherency under In re Spada plus MPEP § 2144.07.

Arad + chemm.hhs.gov

Motivation asserted Per the office action, because Arad teaches a composition reaching a therapeutically effective plasma concentration over time (¶2) but does not specify the claimed plasma concentrations, a PHOSITA would use chemm.hhs.gov's general plasma-concentration range for NAC; and since Arad teaches 600 mg, the plasma concentration would be expected to be higher than chemm's 200-400 mg range. The examiner adds that under In re Spada an identical chemical structure necessarily possesses the claimed properties, and cites MPEP § 2144.07 (selecting a known material for its recognized suitability).

No reasonable expectation of successstrong
chemm.hhs.gov, as characterized in the office action, teaches plasma pharmacokinetics of NAC, whereas claims 10-14 and 25 recite plasma concentrations of NACA (and, in claims 10/12/14, NAC). NACA and NAC are different chemical entities with different physicochemical properties (NACA being an amidated, more lipophilic derivative), so it is contestable under MPEP § 2143.02 whether a PHOSITA would have a reasonable expectation that NAC oral plasma data predicts NACA plasma exposure. Oral absorption/exposure in the pharmaceutical arts is characteristically unpredictable, cutting against a mere hope of the claimed profile. For counsel to weigh.
Otherstrong
Inherency / In re Spada mismatch (analysis): In re Spada inherency applies where the prior art teaches the IDENTICAL chemical structure so that the claimed properties are necessarily present. Here the claimed properties are a PLASMA PROFILE (a dose-, formulation-, and species-dependent behavior in humans), not an intrinsic property of a static chemical structure, and Arad's release-controlled composition is not shown to be structurally identical to the claimed plain NACA tablet. Counsel may weigh whether In re Spada / MPEP § 2112.01 is misapplied to a pharmacokinetic limitation.
Conclusory motivationmoderate
The bridge from chemm's disclosed NAC concentration to the specific claimed ranges rests on the examiner's assertion that a 600 mg dose 'may be expected to be higher' than the 200-400 mg data — a directional, unquantified inference that does not establish arrival at the specific claimed numeric windows (e.g., 200-1200 ng/mL in claim 10; 400-600 ng/mL after 250 mg QD in claims 11-12; 500-1000 ng/mL after 250 mg BID in claims 13-14; the graduated NACA ranges in claim 25). Under MPEP § 2143 / § 2143.01 the reasoning must have a rational underpinning tied to the specific claimed result. For counsel to assess.
Othermoderate
Internal record discrepancy (analysis): the office action states chemm teaches 'a peak plasma concentration of 0.35-4 mg/L (350-400 ng/mL)' — but 0.35-4 mg/L converts to approximately 350-4000 ng/mL, not 350-400 ng/mL. This apparent inconsistency in the examiner's own recitation undermines the precision of the numeric bridge to the claimed ranges and should be confirmed against the actual chemm.hhs.gov text, which is not in the fetched record. The available text does not contain the underlying chemm document.
No reasonable expectation of successmoderate
Several PK claims are tied to a specific dosage form and regimen — 'NACA Tablet, 250 mg' administered QD or BID (claims 11-14). Neither Arad (which discloses controlled-release architectures and, in the cited example, 600 mg) nor chemm (NAC data at 200-400 mg) is shown to teach a 250 mg NACA immediate tablet or its regimen-specific human plasma outcome, so whether a PHOSITA would reasonably expect the specific claimed regimen-dependent values is contestable under MPEP § 2143.02. For counsel to weigh.